The new product integrates venous obstruction prevention and detection capacities whereby both operations are carried out simultaneously during prophylactic therapy.

The device detects venous obstructions in the patients’ circulation whilst they occur and alerts about their formation.

The advantages of the ActiveCare+S.F.T. over the DVT prevention drug, Lovenox, have been proven in a multicenter clinical trial that was conducted by MCS on hip replacement patients in the US.

The new device provides advantage for MCS over the use of medication by providing early detection of those patients in whom preventive treatment has failed.

MCS CEO Adi Dagan said about 90% of the DVT cases are invisible and will not be diagnosed until clinical signs and symptoms are already presented.